表紙:抗ウィルス薬の世界市場 (2021-2028年)
市場調査レポート
商品コード
967430

抗ウィルス薬の世界市場 (2021-2028年)

Global Antiviral Drugs Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.25円
抗ウィルス薬の世界市場 (2021-2028年)
出版日: 2021年07月05日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

抗ウイルス薬市場の成長は、ウイルス感染の発生率の増加によって推進されています。さらに、研究開発活動の増加とワクチンや併用療法などのより新しく高度な製剤の開発は、予測期間の市場成長を促進すると予想されます。

ただし、医薬品開発に伴う高コストと自然療法やホメオパシーなどの代替医療の需要の成長は、市場の成長を抑制します。さらに、予防措置の強化とウイルス感染に対するワクチンの入手可能性についての認識は、抗ウイルス薬の市場成長の抑制要因となります。

当レポートでは、世界の抗ウィルス薬市場について調査し、市場の概要、COVID-19による影響の分析、各セグメントおよび地域別の市場分析と予測、競合情勢の分析、主要企業のプロファイルなどを提供しています。

目次

第1章 世界の抗ウィルス薬市場:調査手法・範囲

  • 調査手法
  • 調査目的と調査範囲

第2章 世界の抗ウィルス薬市場:市場の定義と概要

第3章 世界の抗ウィルス薬市場:エグゼクティブサマリー

  • 市場内訳:薬剤クラス別
  • 市場内訳:タイプ別
  • 市場内訳:アプリケーション別
  • 市場内訳:エンドユーザー別
  • 市場内訳:地域別

第4章 世界の抗ウィルス薬市場:市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界の抗ウィルス薬市場:業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ

第6章 世界の抗ウィルス薬市場:COVID-19分析

  • 市場におけるCovid-19の分析
    • COVID-19以前の市場シナリオ
    • 現在のCOVID-19市場シナリオ
    • COVID-19以降または将来のシナリオ
  • Covid-19中の価格のダイナミクス
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界の抗ウィルス薬市場:薬剤クラス別

  • イントロダクション
  • 市場規模分析、および前年比成長分析 (%):薬剤クラスセグメント別
  • 市場魅力指数:薬剤クラス別
    • 逆転写酵素阻害剤
    • DNAポリメラーゼ阻害剤
    • プロテアーゼ阻害剤
    • ノイラミニダーゼ阻害剤
    • その他

第8章 世界の抗ウィルス薬市場:タイプ別

  • イントロダクション
  • 市場規模分析、および前年比成長分析 (%):タイプ別
  • 市場魅力指数:タイプ別
    • ブランド
    • ジェネリック

第9章 世界の抗ウィルス薬市場:アプリケーション別

  • イントロダクション
  • 市場規模分析、および前年比成長分析 (%):アプリケーション別
  • 市場魅力指数:アプリケーション別
    • HIV
    • 肝炎
    • ヘルペス
    • インフルエンザ
    • その他

第10章 世界の抗ウィルス薬市場:エンドユーザー別

  • イントロダクション
  • 市場規模分析、および前年比成長分析 (%):エンドユーザーセグメント別
  • 市場魅力指数:エンドユーザーセグメント別
    • 病院
    • クリニック
    • 外来手術センター

第11章 世界の抗ウィルス薬市場:地域別

  • イントロダクション
  • 市場規模分析、および前年比成長分析 (%):地域別
  • 市場魅力指数:地域別
  • 北米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析、および前年比成長分析 (%):薬剤クラス別
    • 市場規模分析、および前年比成長分析 (%):タイプ別
    • 市場規模分析、および前年比成長分析 (%):アプリケーション別
    • 市場規模分析、および前年比成長分析 (%):エンドユーザー別
    • 市場規模分析、および前年比成長分析 (%):国別
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第12章 世界の抗ウィルス薬市場:競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • 合併と買収の分析

第13章 世界の抗ウィルス薬市場:企業プロファイル概要

  • Gilead Sciences
    • 企業概要
    • 製品ポートフォリオ・説明
    • 主なハイライト
    • 財務概要
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • AbbVie
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Aurobindo Pharma
  • Dr. Reddy's Laboratories Ltd.

第14章 世界の抗ウィルス薬市場:重要考察

第15章 世界の抗ウィルス薬市場:DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次
Product Code: DMPH2741

Market Overview

The global antiviral drugs market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Antiviral drugs are medicines which are used specially for treating viral infections. Most anti-viral drugs are used for particular viral infections, similar to antibiotics, while a broad-spectrum antiviral drug is effective against a varied range of viruses.

Market Dynamics

The antiviral drugs market growth is driven by increase in the incidence rate of viral infections. In addition, rise in R&D activities and development of newer & advanced formulations, such as vaccines and combination therapy, are expected to drive the market growth in the forecast period.

Increasing viral infection incidences and the rising R&D activities will drive the market growth

According to the WHO, there were around 35.3 million people globally, infected with HIV. Therefore, increased viral infection incidences is one of the important factors that drives the anti-viral drugs market growth. Because of the solid R&D activities, newer and advanced treatments and formulations, such as vaccines, combination therapy and others, are being introduced in the market. Hence, strong R&D is one of the crucial factors in the anti-viral drugs market growth.

For instance, according to data published by the WHO, hepatitis B caused around 887,000 deaths in 2015. Moreover, it was estimated that around 257 million patients were living with hepatitis B virus (HBV) infection in 2015. This is expected to drive the demand for efficient treatment solutions such as antiviral drugs.

Development of new mechanisms and research on second-generation molecules

The development of new mechanisms and research on second-generation molecules, combination therapies, and topical administration routes. Investors proactively pursue research and development of drug candidates for viral diseases that require long-term treatment. They also prefer initiatives that have a predominant patient-base in developed regions of the world and are readily accepted by physicians and drug formularies. Antivirals ideally fit the profile and hence are gaining strong investments.

For instance, according to the Weekly U.S. Influenza Surveillance Report published by the Centers for Disease Control and Prevention (CDC), about 13 million flu cases were reported in 2019. Furthermore, according to data published by WebMD in 2018, around 60.0% of the total U.S. population has been exposed to cytomegalovirus (CMV), with a prevalence of around 90.0% in high-risk groups.

High cost and alternate medicine is likely to hinder the market growth

However, high cost involved in drug development and growth in the demand for alternative medicines such as naturopathy and homeopathy restrain the market growth. In addition, increasing preventive measures and awareness about the availability of vaccines for viral infections act as a restraint to the market growth for antiviral drugs.

COVID-19 Impact Analysis

The rapid spread of the severe acute repiratory syndrome COVID-19, in the immunology human population has lead to aglobal pandemic. While COVID-19 particles may persist on surfaces for several days, as envloped viruses, they are sensitive to desiccation and mild detergent disinfection. The growth of disease, as nasal secretions contain spreadable virus, and contagiousness appears to be highest before or shortly after symptom onset.

Therefore, the Food and Drug Monitoring Agency (BPOM) has issued emergency use authorization (EUA) for two antiviral drugs, favipiravir and remdesivir, to treat COVID-19 patients. Thus, the pandemic will increse the growth of the global antiviral drugs market in the forecast period.

Segment Analysis

Reverse transcriptase inhibitors segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Reverse transcriptase (RT) inhibitors work by blocking the action of reverse transcriptase. The drugs inhibit RNA virus replication by reversible inhibition of viral HIV reverse transcriptase, which reverse transcribes viral RNA into DNA for insertion into the host DNA sequence a sudden inflammation of the pancreas.

This catalyzed transcription is the reverse process of normal cellular transcription of DNA into RNA, hence the names reverse transcriptase and retrovirus. Reverse transcriptase is central to the infectious nature of retroviruses, several of which cause disease in humans, including human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS), and human T-cell lymphotrophic virus I (HTLV-I), which causes leukemia. Reverse transcriptase is also a fundamental component of a laboratory technology known as reverse transcription-polymerase chain reaction (RT-PCR), a powerful tool used in research and in the diagnosis of diseases such as cancer.

Nucleoside reverse transcriptase inhibitors are nucleoside analogues that inhibit the action of the enzyme reverse transcriptase. This enzyme inhibition slows or prevents viral replication. Most of the NRTIs require multiple daily doses, do not interact with other drugs, and can be taken with or without food. Didanosine (ddI), however, can decrease the absorption of other antiretrovirals if they are taken together, and it must be taken on an empty stomach. All NRTIs have been associated, albeit rarely, with a fatal syndrome of lactic acidosis and hepatic steatosis. Tenofovir is a nucleotide reverse transcriptase inhibitor, a subclass distinguished by fewer chemical steps to intracellular activity and a negative charge that effectively keeps the compound in the cell and active longer, allowing once-daily administration. The first antiretroviral drugs to be used, NRTIs remain the backbone of current HIV multidrug regimens.

The branded segment are expected to dominate the antiviral drugs market during the forecast period

The branded drugs are patented drugs. When a pharmaceutical company discovers a new drug, it files for a patent. Branded generics are generic versions of products sold either by the original manufacturer of the patented drug or by generic manufacturers that build up brand equity for their generic versions of the medication, which they introduce right after the patent expires on the original product. and lipases that a normally functioning pancreas would have; therefore, this enzyme would be useful for targeting an isolated problem in the pancreas. Branded generics, sometimes also called as 'value-added generics 'that can either be a novel dosage form of an original patented drug or a generic drug with a definite trade name. Branded generics differ from 'commodity generics' which are pharmaceutical products, generally used as an alternative to innovator products after the expiry of the patent. One of the major differences is the difference in the cost. The brand drugs are far expensive than the generic drugs.

Geographical Analysis

North America region holds the largest market share global antiviral drugs market

North America region is dominating the antiviral drugs market accounted for the largest market share in 2019, owing to the presence of key players in the region, availability of sophisticated healthcare infrastructure, and increasing awareness of viral diseases. In addition, the presence of a strong pipeline for antiviral drugs for the treatment of HIV are expected to increase the product demand.

For instance, according to data published by UNAIDS, globally, around 37.9 million people were living with HIV in 2018. Furthermore, in 2018, around 54.0% of children and 62.0% of adults with HIV were receiving lifelong antiretroviral therapy (ART). This is expected to drive the demand for antiviral drugs in the region.

Competitive Landscape

The antiviral drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Gilead Sciences, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AbbVie, Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, and Dr. Reddy's Laboratories Ltd among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antiviral drugs market globally.

Antiviral Drugs Market Key Companies to Watch

Dr Reddy's Laboratories

Overview: Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, providing medicines through its three businesses segment - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products. The 5000-member team network connects with more than three lakh doctors on a regular basis to ensure that quality medicines we make are available for patients across the length and breadth of the country. The company has progressively transitioned from being a maker of molecules to a provider of medicines. Dr. Reddy's operates in markets across the globe. Company major markets include USA, India, Russia & CIS countries, and Europe.

Product Portfolio: The Company's portfolio has over 200 products covering the whole spectrum of disease areas spanning gastroenterology, oncology, pain management, cardiovascular, dermatology, urology, nephrology, rheumatology and diabetes. Seven brands are listed in Top-300 of the Indian Pharma Market.

Key Development: In August 2020, Dr Reddy's Laboratories launched antiviral drug Avigan (favipiravir) tablets, currently being manufactured by innovator Japanese drug giant Fujifilm Toyama Chemical Co, for the potential treatment of mild to moderate Covid-19 patients in India The agreement that the Hyderabad headquartered generic drug maker entered into grants it exclusive rights for India while it grants both Dr Reddy's and GRA rights to develop, sell and distribute Avigan in all countries other than Japan, China, and Russia.

Why Purchase the Report?

  • Visualize the composition of the antiviral drugs market segmentation by drug class, type, application, and end user highlighting the key commercial assets and players.
  • Identify commercial opportunities in antiviral drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of antiviral drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global antiviral drugs market report would provide an access to an approx. 70 market data table, 65 figures and 300 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Antiviral Drugs Market - By Drug Class

  • Reverse Transcriptase Inhibitors

Nucleoside Reverse transcriptase inhibitors (NRTIs)

Non-nucleoside reverse transcriptase inhibitors (NNRTIs)

  • DNA Polymerase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Other

Global Antiviral Drugs Market - By Type

  • Branded
  • Generic

Global Antiviral Drugs Market -By Application

  • HIV
  • Hepatitis
  • Herpes
  • Influenza
  • Others

Global Antiviral Drugs Market - By End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

Global Antiviral Drugs Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa

Table of Contents

1. Global Antiviral Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Antiviral Drugs Market - Market Definition and Overview

3. Global Antiviral Drugs Market - Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market snippet by Type
  • 3.3. Market snippet by Application
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Global Antiviral Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing viral infection incidences and the rising R&D activities
      • 4.1.1.2. Development of new mechanisms and research on second-generation molecules
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost and alternate medicine is likely to hinder the market growth
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Antiviral Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Antiviral Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Antiviral Drugs Market - By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
    • 7.1.2. Market Attractiveness Index, By Drug Class Segment
  • 7.2. Reverse Transcriptase Inhibitors*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    • 7.2.3. Nucleoside Reverse transcriptase inhibitors (NRTIs)
    • 7.2.4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
  • 7.3. DNA Polymerase Inhibitors
  • 7.4. Protease Inhibitors
  • 7.5. Neuraminidase Inhibitors
  • 7.6. Other

8. Global Antiviral Drugs Market - By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2. Market Attractiveness Index, By Type
  • 8.2. Branded*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    • 8.2.3.
  • 8.3. Generic

9. Global Antiviral Drugs Market - By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. HIV *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Hepatitis
  • 9.4. Herpes
  • 9.5. Influenza
  • 9.6. Others

10. Global Antiviral Drugs Market - By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 10.1.2. Market Attractiveness Index, By End User Segment
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Clinics
  • 10.4. Ambulatory Surgical Centers

11. Global Antiviral Drugs Market - By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Global Antiviral Drugs Market - Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of key companies to watch
  • 12.5. List of the company with disruptive technology
  • 12.6. List of start-up companies

13. Global Antiviral Drugs Market- Company Profiles

  • 13.1. Gilead Sciences *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. F. Hoffmann-La Roche AG
  • 13.3. GlaxoSmithKline plc
  • 13.4. AbbVie
  • 13.5. Merck & Co., Inc.
  • 13.6. Johnson & Johnson Services, Inc.
  • 13.7. Bristol-Myers Squibb Company
  • 13.8. Cipla Inc.
  • 13.9. Aurobindo Pharma
  • 13.10. Dr. Reddy's Laboratories Ltd.

LIST NOT EXHAUSTIVE

14. Global Antiviral Drugs Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us